GlassScriptPhysician profile
Sydney Howard
NPI 1275208886
$4,116.71
in general payments reported to CMS, 2019-2025
24 companies · $2,196 in 2025
The $2,196 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,921 · 2025: $2,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,101 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,100.72 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $839.99 | 2024-2025 | |
| Novo Nordisk INC | $633.35 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $606.10 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $551.60 | 2024-2025 | Jardiance, Mounjaro |
| Pfizer INC. | $425.75 | 2024-2025 | |
| Exact Sciences Corporation | $162.99 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $131.90 | 2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.79 | 2024-2025 | Jardiance, Synjardy |
| Axsome Therapeutics, INC. | $91.03 | 2024-2025 | Auvelity |
| Dexcom, INC. | $77.65 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $63.38 | 2024 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $55.21 | 2024-2025 | Gardasil 9, Vaxelis, Capvaxive |
| Phathom Pharmaceuticals, INC. | $53.24 | 2024-2025 | Voquezna |
| Verona Pharma, INC. | $53.14 | 2025 | Ohtuvayre |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.72 | 2025 | Caplyta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $42.41 | 2025 | Veozah |
| Scpharmaceuticals INC. | $41.06 | 2025 | |
| Corcept Therapeutics | $29.13 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $18.73 | 2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.14 | 2024 | Xifaxan |
| Abbott Laboratories | $18.04 | 2025 | Freestyle Libre 3 |
| Shield Therapeutics INC | $17.33 | 2024 | |
| Amgen INC. | $16.62 | 2025 | Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $15.41 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydney Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.